The COLON Study: Colorectal Cancer Cohort

Conditions

Colorectal Neoplasms Malignant

Keywords

COLON, colorectal cancer, nutrition, lifestyle, survival, recurrence, quality of life

Brief summary

The main aim of this observational, prospective cohort study is to assess associations of diet and other lifestyle factors with colorectal cancer recurrence, survival and quality of life.

Detailed description

The COLON study is a multi-centre prospective cohort study among incident colorectal cancer patients recruited from 12 hospitals in the Netherlands. Patients with colorectal cancer are invited upon diagnosis. Upon recruitment, after 6 months, 2 years and 5 years, patients fill out food-frequency questionnaires; questionnaires about dietary supplement use, physical activity, weight, height, and quality of life; and donate blood samples. Diagnostic CT-scans are collected to assess cross-sectional areas of skeletal muscle, subcutaneous fat, visceral fat and intermuscular fat, and to assess muscle attenuation. Blood samples are biobanked to facilitate future analyse of biomarkers, nutrients, DNA etc. Analysis of serum 25-hydroxy vitamin D levels, B-vitamins and metabolomic profiles are scheduled. A subgroup of patients with colon cancer is asked to provide faecal samples before and at several time points after colon resection to study changes in gut microbiota during treatment. For all patients, information on vital status is retrieved by linkage with national registries. Information on clinical characteristics, including treatment-related toxicity and co-morbidity data, is gathered from linkage with the Netherlands Cancer Registry and with hospital databases or medical records. Hazard ratios will be calculated for dietary and lifestyle factors at diagnosis in relation to recurrence and survival. Repeated measures analyses will be performed to assess changes over time in dietary and other factors in relation to recurrence and survival. The aim is to recruit at least 2000 patients with available data and blood samples.

Klaassen-Dekker N, Zoetendal EG, Capuano E, Winkels RM, van Duijnhoven FJ, van Heek NT, Kruyt FM, Ulvik A, McCann A, Ueland PM, de Wilt JH, Kampman E, Kok DE.

2025-10-10

10.1016/j.ajcnut.2025.10.001

Intake and biomarkers of folate and folic acid as determinants of chemotherapy-induced toxicities in patients with colorectal cancer: a cohort study.

Kok DE, van Duijnhoven FJ, Lubberman FJ, McKay JA, Lanen AV, Winkels RM, Wesselink E, van Halteren HK, de Wilt JH, Ulrich CM, Ulvik A, Ueland PM, Kampman E.

2023-12-076 citations

10.1016/j.ajcnut.2023.11.023

Pre- and post-diagnostic dairy intake in relation to recurrence and all-cause mortality in people with stage I-III colorectal cancer.

van Lanen AS, Kok DE, Wesselink E, Winkels RM, van Halteren HK, de Wilt JHW, Kampman E, van Duijnhoven FJB.

2023-07-022 citations

10.1007/s00394-023-03201-0

Diet quality indices and dietary patterns are associated with plasma metabolites in colorectal cancer patients.

Geijsen AJMR, Kok DE, van Zutphen M, Keski-Rahkonen P, Achaintre D, Gicquiau A, Gsur A, Kruyt FM, Ulrich CM, Weijenberg MP, de Wilt JHW, Wesselink E, Scalbert A, Kampman E, van Duijnhoven FJB.

2021-02-0512 citations

10.1007/s00394-021-02488-1

The association between the adapted dietary inflammatory index and colorectal cancer recurrence and all-cause mortality.

Wesselink E, Staritsky LE, van Zutphen M, Geijsen AJMR, Kok DE, Kruyt F, Veenstra RP, Spillenaar Bilgen EJ, Kouwenhoven EA, de Wilt JHW, Kampman E, van Duijnhoven FJB.

2021-01-1115 citations

10.1016/j.clnu.2021.01.004

Vitamin D, magnesium, calcium, and their interaction in relation to colorectal cancer recurrence and all-cause mortality.

Wesselink E, Kok DE, Bours MJL, de Wilt JHW, van Baar H, van Zutphen M, Geijsen AMJR, Keulen ETP, Hansson BME, van den Ouweland J, Witkamp RF, Weijenberg MP, Kampman E, van Duijnhoven FJB.

2020-05-0140 citations

10.1093/ajcn/nqaa049

Chemotherapy and vitamin D supplement use are determinants of serum 25-hydroxyvitamin D levels during the first six months after colorectal cancer diagnosis.

Wesselink E, Bours MJL, de Wilt JHW, Aquarius M, Breukink SO, Hansson B, Keulen ETP, Kok DE, van den Ouweland J, van Roekel EH, Snellen M, Winkels R, Witkamp RF, van Zutphen M, Weijenberg MP, Kampman E, van Duijnhoven FJB.

2020-01-0712 citations

10.1016/j.jsbmb.2020.105577

Interventions

OTHERNo intervention: observational study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

No

Inclusion criteria

\- Patients newly diagnosed with colorectal cancer in one of the participating hospitals

Exclusion criteria

* Non-Dutch speaking * A history of colorectal cancer or (partial) bowel resection * Chronic inflammatory bowel disease * Hereditary colorectal cancer syndromes (Lynch syndrome, FAP, Peutz-Jegher) * Dementia or another mental condition that makes it impossible to fill out questionnaires

Design outcomes

Primary

Measure	Time frame	Description
Survival	An average follow-up of at least 5 years	Overall survival
Cancer recurrence	An average follow-up of at least 5 years	Cancer recurrence
Quality of life (EORTC QLQ-C30)	An average follow-up of at least 5 years	Quality of life

Secondary

Measure	Time frame	Description
Chemotherapy-induced toxicity (QLQ-CIPN20)	12 months after diagnosis	Chemotherapy-induced peripheral neuropathy
Microbiota composition based on 16S rRNA profiling	At diagnosis and 6, 12 and 35 weeks after resection	Stool samples
Co-morbidities	An average follow-up of at least 5 years	—

Countries

Netherlands

Outcome results

None listed